Research Analysts Set Expectations for DFTX Q3 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – HC Wainwright lowered their Q3 2026 EPS estimates for shares of Definium Therapeutics in a research note issued on Monday, August 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.53) per share for the quarter, down from their prior estimate of ($0.46). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($3.05) EPS, Q1 2027 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($1.71) EPS, FY2028 earnings at $0.33 EPS, FY2029 earnings at $2.99 EPS and FY2030 earnings at $5.87 EPS.

Several other research analysts have also recently issued reports on the company. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Stifel Nicolaus raised their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Needham & Company LLC upped their target price on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $55.00.

Definium Therapeutics Stock Down 9.4%

Definium Therapeutics stock opened at $40.91 on Wednesday. Definium Therapeutics has a one year low of $8.70 and a one year high of $49.70. The stock has a fifty day moving average of $38.68 and a 200 day moving average of $26.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The stock has a market cap of $4.08 billion, a PE ratio of -11.93 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89).

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after buying an additional 6,148 shares in the last quarter. Creative Planning increased its stake in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after buying an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after acquiring an additional 2,342 shares during the period. Rhumbline Advisers lifted its position in shares of Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after acquiring an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the sale, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 48,096 shares of company stock worth $2,165,763 over the last ninety days. 2.40% of the stock is owned by corporate insiders.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright still forecasts Definium Therapeutics becoming profitable in FY2028, with projected earnings of $0.33 per share, followed by $2.99 in FY2029 and $5.87 in FY2030. However, all three estimates were reduced from prior forecasts, limiting the positive impact.
• Neutral Sentiment: Reported short interest remained at zero shares as of August 11, with a days-to-cover ratio of zero. This indicates no measurable short-selling pressure, although it also provides little evidence of strong bearish positioning.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $3.05 from a loss of $2.10, and reduced its FY2027 forecast to a loss of $1.71 from $1.22. Quarterly estimates were also cut for Q3 and Q4 2026 and all four quarters of 2027, reflecting expectations for prolonged operating losses.
• Negative Sentiment: Longer-term projections weakened as well: FY2028 EPS was reduced to $0.33 from $0.77, FY2029 to $2.99 from $3.26, and FY2030 to $5.87 from $5.98. The broad-based cuts undermine confidence in the pace of the company’s future earnings growth.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.